Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AlphaVax's novel alphavaccine technology has been shown to be effective in generating protection against congenital cytomegalovirus disease in a preclinical study, the company has reported.
Subscribe to our email newsletter
In the study published in the March issue of the Journal of Infectious Disease, guinea pigs immunized with the CMV alphavaccine before becoming pregnant and infected with CMV had greatly reduced amounts of virus in their blood and gave birth to significantly more live pups compared to guinea pigs not receiving the vaccine. The guinea pig model is used for preclinical testing of novel vaccines because the guinea placenta is similar to that of humans.
CMV is a genus of Herpes viruses, and although poses little risk to healthy adults, can be dangerous to immunocompromised patients and also cause birth defects. AlphaVax recently announced the acceptance of an Investigational New Drug (IND) application by the FDA to begin clinical trials evaluating a vaccine for CMV developed with the company’s alphavaccine technology.